Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 11/20 | 0.49 |
| ▸ | GPBAR1 | Q8TDU6 | 6/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3559191 | 0.88 | GPBAR1 (0.54) | CETPGPBAR1TACR1 | |
| SCHEMBL3557843 | 0.85 | CETP (0.50) | CETPGPBAR1TACR1 | |
| SCHEMBL1893336 | 0.85 | CETP (0.67) | CETPTBXA2RPTGDRPTGDR2 | |
| SCHEMBL5669323 | 0.79 | CETP (0.50) | CETPGPBAR1TACR1 | |
| SCHEMBL4847533 | 0.77 | CETP (0.46) | CETPGPBAR1TACR1TBXA2RPTGDR | |
| SCHEMBL4186842 | 0.76 | GAA (0.49) | CETPGPBAR1PTGDR2 | |
| SCHEMBL3553272 | 0.76 | CETP (0.56) | CETPGPBAR1TACR1TBXA2RPTGDR | |
| SCHEMBL3556844 | 0.75 | CETP (0.48) | CETPGPBAR1TACR1 | |
| SCHEMBL20768063 | 0.75 | CETP (0.42) | CETPGPBAR1TACR1 | |
| SCHEMBL3556005 | 0.75 | CETP (0.85) | CETPTBXA2RPTGDRPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737811-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-08-10 | — | — | EP | disclosed |
| US-8193365-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100249024-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7737295-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-06-15 | — | — | US | disclosed |
| EP-1737811-A4 | CETP INHIBITORS | MERCK & CO INC (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1951053-A2 | CETP INHIBITORS | Merck & Co., Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070225365-A1 | Cetp Inhibitors | MERCK & CO., INC. (US) | 2007-09-27 | — | — | US | disclosed |
| WO-2007047591-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| EP-1737811-A1 | CETP INHIBITORS | Merck & Co., Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005100298-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225365-A1 | Cetp Inhibitors | CETP, APOB, NPC1 | CETP 1/4885GPBAR1 286/4885TACR1 3645/4885 |
| US-20100249024-A1 | CETP INHIBITORS | CETP, APOB, NPC1 | CETP 1/4885GPBAR1 286/4885TACR1 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.